Articles related to CLINICAL STUDY

The latest systematic review on olanzapine for schizophrenia treatment has defined a therapeutic reference range of 20-40 ng/mL, offering insight into optimal efficacy and tolerable levels. Explore the full study to understand how these findings can inform clinical practice and patient care.

The study on the use of subcutaneous racemic ketamine in treatment-resistant depression underscores the significance of a flexible, individualized dosing approach over a 4-week course.

This comprehensive research highlights favorable outcomes with Cigna’s home-redirection program for pegfilgrastim administration in CIN prophylaxis, including a 32% reduction in specific complications. Explore how this study may influence future healthcare delivery models, enhancing both clinical efficacy and affordability.

The first of its kind in Cyprus, this study underscores a prevailing lack of public knowledge regarding paracetamol, including misunderstandings about its composition and concerning practices such as combining it with alcohol.

The SAGE-AF study provides valuable insights into the cost-reducing behaviors among older adults with atrial fibrillation, highlighting the need for targeted interventions, especially for those with cognitive impairments. Explore the study to understand how these behaviors are shaping medication management in this vulnerable population.

Exploring new avenues for treating depression in youth, this compelling research showcases the potential of physical activity interventions in significantly reducing depressive symptoms, particularly among those aged 13 years and above. Find out how this accessible, non-pharmacological approach could transform pediatric mental health care.